Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

被引：0
|
作者：
Hong, David S.
Strickler, John H.
Fakih, Marwan
Falchook, Gerald Steven
Li, Bob T.
Durm, Greg Andrew
Burns, Timothy F.
Ramalingam, Suresh S.
Goldberg, Sarah B.
Frank, Richard C.
Marrone, Kristen
Shu, Catherine A.
Gandara, David R.
Soman, Neelesh
Henary, Haby Adel
Govindan, Ramaswamy
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] City Hope Comprehens Med Ctr, Duarte, CA USA
[4] Sarah Cannon Res Inst, Denver, CO USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Yale Sch Med, New Haven, CT USA
[10] Nuvance Hlth, Norwalk, CT USA
[11] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Columbia Univ, Med Ctr, New York, NY USA
[13] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[14] Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA
[15] Amgen Inc, Thousand Oaks, CA 91320 USA
[16] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS2669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2669
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer
    Blumenschein, George R., Jr.
    Reckamp, Karen
    Stephenson, G. Joe
    O'Rourke, Timothy
    Gladish, Gregory
    McGreivy, Jesse
    Sun, Yu-Nien
    Ye, Yining
    Parson, Mandy
    Sandler, Alan
    CLINICAL CANCER RESEARCH, 2010, 16 (01) : 279 - 290
  • [22] A PHASE 1B STUDY OF AMG 655 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Paz-Ares, L.
    Torres, J. M. Sanchez
    Diaz-Padilla, I.
    Links, M.
    Reguart, N.
    Boyer, M.
    Wiezorek, J.
    Sabin, T.
    Hsu, M.
    Van Meerbeeck, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [23] HERALD: A PHASE 1B/2 TRIAL OF HER3 INHIBITOR U3-1287 IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Von Pawel, Joachim
    Tseng, Jennifer
    Dediu, Mircea
    Schumann, Christian
    Copigneaux, Catherine
    Beckman, Robert A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S119 - S120
  • [24] Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Vizcarrondo, F. R.
    Patel, S. P.
    Pennell, N. A.
    Pakkala, S.
    West, H.
    Kratzke, R.
    Tarazi, J.
    Wilner, K.
    Polli, A.
    Tan, W.
    Liu, Y.
    Valota, O.
    Piperdi, B.
    Reckamp, K. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
    Sanjay Goel
    Umang Swami
    Kirushna Kumar
    Christian Dittrich
    Larisa Reyderman
    Minish Jain
    Joseph Aisner
    James Song
    Daniel P. Petrylak
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 567 - 578
  • [26] A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
    Goel, Sanjay
    Swami, Umang
    Kumar, Kirushna
    Dittrich, Christian
    Reyderman, Larisa
    Jain, Minish
    Aisner, Joseph
    Song, James
    Petrylak, Daniel P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 567 - 578
  • [27] Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).
    Spira, Alexander I.
    Wilson, Frederick Hugh
    Shapiro, Geoffrey
    Dooms, Christophe
    Curioni-Fontecedro, Alessandra
    Esaki, Taito
    Barlesi, Fabrice
    Cocks, Kim
    Trigg, Andrew
    Stevinson, Kendall
    Matsuda, Tara
    Tran, Qui
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [29] A phase lilt and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)
    Byers, L.
    Gerber, D.
    Peguero, J.
    Micklem, D.
    Yule, M.
    Lorens, J. B.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S18 - S19
  • [30] KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
    Spira, Alexander I.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca Suk
    Ou, Sai-Hong Ignatius
    Pacheco, Jose Maria
    Johnson, Melissa Lynne
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo Vailati
    Pennell, Nathan A.
    Zhang, Jun
    Velastegui, Karen
    Christensen, James G.
    Yan, Xiaohong
    Anderes, Kenna Lynn
    Chao, Richard C.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345